[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,43,79,118,147,189,212,234,255,273,300,320,340,362,385,406,427,448,470,488,506,528,548,565,580],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100608491","phase-2-metabolic-interventions-time-restricted-eating-glp1-receptor-agonist-and-heart-healthy-diet-to-improve-cardiometabolic-health-in-prostate-cancer-patients-during-androgen-deprivation-therapy-impact-adt-trial-100608491",false,"NCT07202247","Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial","A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen Deprivation Therapy (IMPACT-ADT)","Inclusion Criteria:\n\n* Documented informed consent of the participant\n* English, Spanish or Mandarin-speaking\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Male\n* Aged: 30-79\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* High burden of cardiovascular comorbidities who would be eligible for insurance coverage for GLP1-RA therapy defined as:\n\n  * Body mass index (BMI) of ≥ 30 kg\u002Fm\\^2 or\n  * BMI ≥ 27 kg\u002Fm\\^2 in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, dyslipidemia)\n* Prostate cancer defined as one of the following:\n\n  * National Comprehensive Cancer Network (NCCN) intermediate risk prostate cancer receiving definitive radiation with a plan to undergo ADT for 6 months\n  * Biochemical persistent or recurrent prostate cancer status post prostatectomy receiving salvage radiation with a plan to undergo ADT for 6 months\n\nExclusion Criteria:\n\n* Currently engaging in strict macronutrient\u002Ftime limited diet, including ketogenic, low-carb, paleo, or warrior diet\n* Currently under GLP1-RA therapy\n* Poorly controlled diabetes\n* Unable to undergo time-restricted diet\n* Contraindications for GLP1-RA therapy: including hypersensitivity to the drug, personal history of pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, end-stage renal disease\n* Other active disease deemed not eligible to participant in the study according to treating physician\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","MALE","30 Years","79 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.",[28,29],"Prostate Carcinoma","Recurrent Prostate Carcinoma","RECRUITING","2026-08-13",{"date":33,"type":34},"2026-08-17","ACTUAL",{"date":36,"type":34},"2025-11-05",{"date":38,"type":22},"2028-04-09",{"name":40,"class":41},"City of Hope Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100592628","the-vanguard-study-testing-a-new-way-to-screen-for-cancer-100592628","NCT06995898","The Vanguard Study: Testing a New Way to Screen for Cancer","Inclusion Criteria:\n\n* Ages 45-75 years old\n* Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment\n* Agree to allow collection of information from their medical records for study-related purposes\n* Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic\n\n  * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion\n\nExclusion Criteria:\n\n* Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years\n\n  * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible. Persons with a history of prostate cancer that has not been treated are not eligible, regardless of when the diagnosis occurred\n* Ongoing cancer diagnostic work-up\n* Ongoing participation in another study of an investigational cancer screening test or technology not currently utilized in routine clinical practice\n* Currently breastfeeding or pregnant, or planning to become pregnant in the next year\n* History of solid organ or hematopoietic transplantation at any time, or blood transfusion within the last 30 days",true,"ALL","45 Years","75 Years",{"count":54,"type":22},24000,[56],"NA","The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).",[59,60,61,62,63,64,65,66,67,68,28],"Bladder Carcinoma","Breast Carcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Liver Carcinoma","Lung Carcinoma","Malignant Solid Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma",{"date":70,"type":34},"2026-08-14",{"date":72,"type":34},"2025-06-18",{"date":74,"type":22},"2029-06-30",{"name":76,"class":77},"National Cancer Institute (NCI)","NIH",40,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":110,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100589690","phase-2-proof-of-concept-trial-to-assess-the-efficacy-and-safety-of-fezolinetant-in-improving-vasomotor-symptoms-in-men-with-prostate-cancer-undergoing-androgen-deprivation-therapy-100589690","NCT06957691","Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy","Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)","Fezo-ADT","Inclusion Criteria:\n\n* Male sex\n* Age 40 years and older\n* Diagnosis of prostate cancer\n* Androgen deprivation therapy\n* Presence of 5 or more moderate-to-severe hot flashes per day or 35 or more moderate-to-severe hot flashes per week\n* Ability to sign the inform consent\n* Willing to use reliable methods of contraception if partner is of childbearing age\n* Ability to record hot flashes electronically\n\nExclusion Criteria:\n\n* Use of abiraterone acetate\n* Use of docetaxel and other chemotherapeutic agents\n* Liver cirrhosis\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper limit of normal\n* Total bilirubin above the upper limit of normal\n* Glomerular filtration rate \\\u003C 30 mL\u002Fmin\n* Use of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, sedatives, or hypnotics if prescribed for the treatment of hot flashes\n* Use of over-the-counter hormonal agents or herbal compounds\n* Current use of CYP1A2 inhibitors\n* Ingestion of alcohol within 2 weeks prior to the baseline visit\n* Inability to abstain from alcohol use during the study period.","40 Years",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.\n\nThe main questions it aims to answer are:\n\n* Does fezolinetant improve the frequency and severity of hot flashes?\n* Does fezolinetant cause any harm to the liver?\n* Does fezolinetant improve quality of life, sleep quality, fatigue, mood, sexual function, and metabolic parameters?\n\nResearchers will compare how people respond to fezolinetant versus a placebo, which does not contain any active medicine.\n\nParticipants will:\n\n* Take fezolinetant or a placebo every day for 4 weeks\n* Visit the clinic once every 2 weeks for checkups and tests\n* Keep a diary of the number of times and intensity that they experience hot flashes",[92,93,94,95,28,96,97,98,99,100,101,102,103,104,105,106,107,108,109],"Prostate Cancer","Prostate Cancer (Adenocarcinoma)","Prostate Cancer Metastatic Disease","Prostate Cancer Recurrent","Prostate Neoplasm","Prostate Adenocarcinoma","Prostate Cancer With Bone Metastasis","Vasomotor Disturbance","Vasomotor Symptoms","Vasomotor Symptoms (VMS)","Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men","Vasomotor Symptoms; Hot Flashes","Androgen Deprivation Therapy","Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma","Androgen-deprivation Therapy","Hot Flashes","Hot Flushes","Hot Flushes and\u002For Sweats",[104,107,108,92,100],{"date":33,"type":34},{"date":113,"type":34},"2026-01-14",{"date":115,"type":22},"2028-12-31",{"name":117,"class":41},"Shehzad Basaria, M.D.",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":52,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100571243","phase-3-low-intensity-extracorporeal-shockwave-therapy-on-penile-rehabilitation-after-robot-assisted-surgical-treatment-of-genitourinary-cancers-100571243","NCT06717711","Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers","RCT_LiESWT","Inclusion Criteria:\n\n* Patients aged ≤75 yrs;\n* PSA \\\u003C10 ng\u002FmL\n* Prostate Cancer ISUP grade ≤2 and cT≤2 at prostate biopsy\n* undergoing nerve sparing RARP;\n* preoperative IIEF-5 score ≥ 17;\n* First PSA (45d after surgery) \\\u003C0.1\n* Prostate Cancer ISUP grade ≤2 pT\\\u003C3b and at final pathology\n* ≥ 18 yrs old;\n* compliants patients able to follow the study protocol and fill in IIEF-5 scores and EORTC quality of life questionnaires;\n* patients able to provide a written informed consent for the trial.\n\nExclusion Criteria:\n\n* anaesthesiologic contraindications to robotic surgery\n* patients submitted to pelvic radiotherapy or androgen deprivation\n* patients reporting major postoperative complications (CD≥3)\n* cardiovascular contraindications to PDE5i medical treatment","18 Years",{"count":127,"type":22},158,[129],"PHASE3","This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical Prostatectomy (RP) erectile dysfunction (ED) in addition to PDE5 inhibitors (PDE5i) versus PDE5i alone. Our hypothesis is that early andrological rehabilitation that combines Li-ESWT and PDE5i could lead to faster and better recovery of valid erections for intercourse, with a greater rate of postoperative International Index of Erectile Function-5 (IIEF-5) compared to patients receiving PDE5i alone.",[28,132,133],"Erectile Function","Genito Urinary Cancer",[135,136,137,138],"prostate cancer","erectile function","rehabilitation","genitourinary cancers",{"date":70,"type":34},{"date":141,"type":34},"2023-09-15",{"date":143,"type":22},"2028-02-28",{"name":145,"class":41},"Regina Elena Cancer Institute",2,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":50,"minAge":125,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":42},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":155,"type":22},27,[25],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[159,160,161,59,60,162,61,163,164,165,166,167,168,169,170,65,66,171,172,173,174,175,67,68,176,28,177,178,179],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Cervical Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Primary Peritoneal Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-07-28",{"date":182,"type":34},"2026-07-30",{"date":184,"type":34},"2025-12-18",{"date":186,"type":22},"2026-12-18",{"name":188,"class":41},"Mayo Clinic",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":42},"100472951","mri-guided-transurethral-urethral-ultrasound-ablation-for-the-treatment-of-low-to-intermediate-grade-prostate-cancer-100472951","NCT05438563","MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer","Focal Prostate Ablation for Low to Intermediate Grade Cancer Utilizing TULSA Profound System","Inclusion Criteria:\n\n* Male\n* Age 45-80 years, with \\> 10 years life expectancy\n* Biopsy-confirmed, NCCN \\[Gleason Grade (GG) 1, favorable GG 2 and unfavorable GG3\\] intermediate-risk prostate cancer\n* Stage =\\\u003C T2c, N0, M0\n* International Society of Urological Pathology (ISUP) grade group 1, 2, or 3 disease on transrectal ultrasonography (TRUS)-guided biopsy (minimum 8 cores, combination of systematic and MRI fusion-guided) or in-bore biopsy \\[minimum 3 cores from each Prostate Imaging-Reporting and Data System (PI-RADS) version (v)2 category \\>= 3 lesion\\]. Biopsy reported within 12 months of baseline visit, with minimum 6-week interval between biopsy and baseline\n* Prostate specific antigen (PSA) =\\\u003C 20 ng\u002FmL reported within 3 months of baseline\n* Treatment naive\n* Planned ablation volume \\\u003C 3.0 cm axial radius from the urethra on mpMRI acquired within 6 months of baseline\n\nExclusion Criteria:\n\n* Inability to undergo MRI or general anaesthesia\n* Suspected tumour \\> 30 mm from the prostatic urethra or \\\u003C 14 mm from the prostatic urethra\n* Prostate calcifications \\> 3 mm in maximum extent obstructing ablation of tumor on low-dose pelvic computed tomography (CT)\n\n  * Criteria subject to additional review and approval by sponsor. Alternatively, prospective TRUS to query calcifications or susceptibility-weighted MRI if available may be used to assess calcification. Imaging for calcification screening must be dated within 1 year of baseline visit\n* Unresolved urinary tract infection or prostatitis\n* History of proctitis, bladder stones, hematuria, history of acute urinary retention, severe neurogenic bladder\n* Artificial urinary sphincter, penile implant or intraprostatic implant\n* Less than 10 years life expectancy\n* Patients who are otherwise not deemed candidates for radical prostatectomy (RP)\n* Inability or unwillingness to provide informed consent\n* History of anal or rectal fibrosis or stenosis, or urethral stenosis, or other abnormality challenging insertion of devices","80 Years",{"count":198,"type":22},100,[56],"This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer. MRI-guided TULSA ablation is a minimally invasive procedure that uses an ultrasound device guided by MRI imaging to deliver high-energy sound waves, producing very high temperature to ablate (destroy) tumor cells in a targeted manner. The MRI-guided TULSA procedure may help patients avoid surgery and help improve prostate cancer patients' quality of life.",[28,202,203],"Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","2026-07-21",{"date":206,"type":34},"2026-07-22",{"date":208,"type":34},"2022-04-06",{"date":210,"type":22},"2028-12-07",{"name":188,"class":41},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":42},"100428320","early-phase-1-99mtc-psma-is-biodistribution-in-patients-with-prostate-cancer-100428320","NCT04857502","99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer","99mTc-PSMA-I&Amp;S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation","Inclusion Criteria:\n\n* Men with PCa (primary or recurrent disease)\n* Men who received a 68Ga-PSMA-11 positron emission tomography (PET)\u002Fcomputed tomography (CT) for staging or restaging\n* Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET\u002FCT\n* Men who are scheduled for pelvic LN dissection (PLND)\n* Men who can provide oral and written informed consent\n* Men who can comply with study procedures\n\nExclusion Criteria:\n\n* Patients who started any PCa treatment between study enrollment and surgery\n* Technically inaccessible nodal location",{"count":220,"type":22},30,[222],"EARLY_PHASE1","This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.",[28,29],"2026-07-16",{"date":227,"type":34},"2026-07-17",{"date":229,"type":34},"2021-04-27",{"date":231,"type":22},"2028-06-01",{"name":233,"class":41},"Jonsson Comprehensive Cancer Center",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":42},"100582627","phase-2-an-investigational-scan-18f-rhpsma-73-pet-mpmri-for-targeted-prostate-biopsy-using-trus-mr-fusion-technique-100582627","NCT06865768","An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique","Prospective Phase II Validation of the Performance of a Prostate-Specific Membrane Antigen (PSMA) Radiotracer for Positron Emission Tomography-Multiparametric Magnetic Resonance (PET-mpMR) Imaging to Target Prostate Biopsy Via Transrectal Ultrasound (TRUS) -Magnetic Resonance Imaging (MRI) Fusion Technique","Inclusion Criteria:\n\n* Male subjects aged \\> 18 years\n* Patients with suspected prostate cancer who will have prostate biopsy for confirmation\n* Ability to lie still for MRI scanning\n* Patients must be able to provide written informed consent\n\nExclusion Criteria:\n\n* Documented acute prostatitis, symptomatic or severe benign prostatic hyperplasia (BPH) or urinary tract infections\n* Patients with contraindications for MRI including implantable pace makers, cochlear implants\n* Patients with uni- or bilateral hip prosthesis\n* Subjects with other significant medical conditions that would create unacceptable prostate biopsy risk, compromise retention on study or compromise study related assessments\n* Prostate biopsy within 4 weeks prior to entry on this study in which inflammation might affect PET-mpMR result\n* Is determined by the Investigator that the patient is clinically unsuitable for the study\n* Is incapable of understanding the language in which the information for the patient is given\n* Participation in a concurrent clinical trial or in another trial within the past 30 days",{"count":242,"type":22},90,[25],"This phase II trial evaluates an imaging technique called 18F-rhPSMA-7.3 positron emission tomography (PET)-multiparametric (mp) magnetic resonance imaging (MRI) in identifying tumor tissue in men suspected to have prostate cancer. This clinical trial also seeks to determine if the abnormal tissue identified during imaging represents the tumor tissue removed during transrectal ultrasound-magnetic resonance imaging (TRUS-MR) fusion biopsy of the prostate. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 18F-rhPSMA-7.3. Because some tumors take up 18F-rhPSMA-7.3 it can be seen with PET. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. These pictures can show the difference between normal and diseased tissue. Standard of care imaging for prostate cancer includes mpMRI, which is the combination of multiple magnetic resonance techniques, including diffusion weighted imaging, dynamic contrast-enhanced imaging, and spectroscopy, to achieve an image that will allow for better identification of tumor size and location, as well as possibly identifying tumor spread and aggressiveness. However, mpMRI may not be as effective in identifying prostate tumors that are clinically significant. A TRUS-MR biopsy involves using both ultrasound and MRI scans to locate abnormal areas in the prostate. An 18F-rhPSMA-7.3 PET-mpMRI may be more effective than mpMRI alone in identifying tumor tissue and may increase the accuracy of TRUS-MRI fusion biopsies in men suspected of having prostate cancer.",[28],"2026-07-13",{"date":248,"type":34},"2026-07-14",{"date":250,"type":34},"2025-04-18",{"date":252,"type":22},"2029-12-31",{"name":254,"class":41},"Emory University",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":42},"100421236","integrating-quantitative-mri-and-artificial-intelligence-to-improve-prostate-cancer-classification-100421236","NCT04765150","Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification","Inclusion Criteria:\n\n* Male patients 18 years of age and older\n* Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer\n* Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)\n* Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent\n* Prior radiotherapy",{"count":262,"type":22},275,"OBSERVATIONAL","This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.",[28],"2026-07-02",{"date":268,"type":34},"2026-07-07",{"date":270,"type":34},"2021-04-01",{"date":231,"type":22},{"name":233,"class":41},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":42},"100435211","phase-2-androgen-ablation-therapy-with-or-without-niraparib-after-radiation-therapy-for-the-treatment-of-high-risk-localized-or-locally-advanced-prostate-cancer-100435211","NCT04947254","Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer","Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer","Inclusion Criteria:\n\n* Completion of informed consent prior to any study specific procedures. Consent may be done remotely.\n* Patients must agree to tissue collection for correlative studies at the specified timepoints\n* Male aged 18 years and above\n* Histologically or cytologically confirmed prostate carcinoma\n* Localized or regional high-risk disease as defined by at least one of the following features: Prostate specific antigen (PSA) \\> 20 ng\u002FmL, T3a or higher, grade group 4-5 (i.e. Gleason score ≥ 8) as per National Comprehensive Cancer Network (NCCN) Prostate Cancer Version 2.2020 for high risk or very high risk prostate cancer, and\u002For regional lymph nodes positive for prostate cancer\n* Planned for definitive treatment of local regional prostate cancer using XRT and androgen ablation\n* Willing to undergo ongoing medical castration to maintain testosterone levels of ≤ 50 ng\u002FdL (≤ 2.0 nM) throughout systemic treatment or have undergone bilateral orchiectomy\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. Patients must have adequate organ and bone marrow function measured within 7 days prior to treatment registration as defined below:\n* Hemoglobin ≥ 10.0 g\u002FdL\n* Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL\n* White blood cells (WBC) \\> 3 x 10\\^9\u002FL\n* No features suggestive of myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) on peripheral blood smear\n* Platelet count ≥ 100 x 10\\^9\u002FL\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (except for patients with known Gilbert's disease). (Note: In subjects with Gilbert's syndrome, if total bilirubin is \\> 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤ 1.5 x ULN, subject may be eligible.)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 2.5 x institutional upper limit of normal\n* Calculated creatinine clearance (Cockcroft-Gault Equation) ≥ 30 mL\u002Fmin\n* Serum Albumin ≥ 3.0\n* Serum potassium ≥ 3.5 mmol\u002FL\n* Able to swallow study drugs whole as a tablet\u002Fcapsule\n* Patients who have partners of childbearing potential (e.g. female that has not been surgically sterilized or who are not amenorrheic for ≥ 12 months) must be willing to use two methods of birth control including adequate barrier protection during the study and for 4 months after last dose of niraparib, abiraterone acetate, and\u002For apalutamide administration. In addition men should not donate sperm during this period. Please note that the efficacy of hormonal contraception may be decreased if administered with niraparib, abiraterone acetate, and\u002For apalutamide\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n* Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry\n\nExclusion Criteria:\n\n* Any prior systemic treatment for prostate cancer with the exception of ADT started within 6 months of trial enrollment. Any prior PARP inhibitor therapy\n* Patients who have prostate cancer with distant metastatic disease\n* Patients who have had prior major surgery (prostatectomy) or radiotherapy for the treatment of prostate cancer\n* Any unresolved toxicity (Common Terminology Criteria for Adverse Events \\[CTCAE\\] grade ≥ 2) from previous anti-cancer therapies\n* History or current diagnosis of MDS\u002FAML, and\u002For history of any malignancy \\[other than the one treated in this study\\] which has a ≥ 30% probability of recurrence within 24 months (except for adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix or Ta urothelial carcinomas)\n* Active uncontrolled infection (patients completing a course of antibiotic or antiviral therapy whose infection is deemed to be controlled may be allowed on study after discussion with the principal investigator \\[PI\\]; the PI will serve as the final arbiter regarding eligibility)\n* Active or symptomatic viral hepatitis or chronic liver disease\n* Active pneumonitis or extensive bilateral lung disease of non-malignant etiology\n* Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events. Examples include, but are not limited to superior vena cava syndrome, extensive bilateral lung disease on high resolution computed tomography (HRCT) scan, uncontrolled seizures, history of allogeneic organ transplant, history of primary immunodeficiency or any psychiatric disorder that prohibits obtaining informed consent\n* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of study medication\n* Patients with a known hypersensitivity to niraparib, apalutamide, and\u002For abiraterone acetate\n* Prisoners or subjects who are involuntarily incarcerated\n* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness\n* Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system \\[CNS\\] or meningeal disease which may require treatment with surgery or radiation therapy)\n* Severe or unstable angina, myocardial infarction (within 6 months prior to enrollment), symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), uncontrolled hypertension, or clinically significant ventricular arrhythmias within 6 months prior to randomization\n* Current evidence of any of the following:\n\n  * Gastrointestinal disorder affecting absorption\n  * Active uncontrolled infection (e.g., human immunodeficiency virus \\[HIV\\] or viral hepatitis)\n  * Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone\u002Fprednisolone once daily\n  * Avoid concomitant strong CYP3A4 inducers during abiraterone acetate treatment. If a strong CYP3A4 inducer must be co-administered, increase the abiraterone acetate dosing frequency\n  * Avoid co-administration of abiraterone acetate with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate\n  * Baseline moderate and severe hepatic impairment (Child-Pugh class B \\& C)\n  * Any condition that in the opinion of the investigator, would preclude participation in this study",{"count":281,"type":22},200,[25],"This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread to nearby tissue or lymph nodes (locally advanced). Androgen ablation therapy (also known as hormone therapy) lowers the levels of male hormones called androgens in the body. Androgens stimulate prostate cancer cells to grow. There are 2 types of androgen ablation therapy given in this study: AAP + ADT and Apa + ADT. AAP + ADT is the treatment combination of the drugs abiraterone acetate and prednisone (AAP) given with androgen deprivation therapy (ADT, also known as androgen deprivation therapy or androgen suppression medication, which is used as standard of care to lower testosterone levels in men with high risk localized or metastatic prostate cancer). Apa + ADT is the treatment combination of the drug apalutamide (Apa) given with ADT. Androgen ablation therapy with or without niraparib after radiation therapy may help to control the disease in patients with prostate cancer.",[28,285,286,287,288,289,290],"Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","2026-06-19",{"date":293,"type":34},"2026-06-23",{"date":295,"type":34},"2021-08-05",{"date":297,"type":22},"2028-06-07",{"name":299,"class":41},"M.D. Anderson Cancer Center",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":146},"100564120","phase-3-radiation-therapy-with-rapidplan-knowledge-based-planning-vs-human-driven-planning-for-treatment-of-prostate-cancer-100564120","NCT06625034","Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer","Randomized Phase III Trial of Rapid-Plan Knowledge-Based Planning vs. Human-Driven Planning for Prostate Cancer Radiotherapy","Inclusion Criteria:\n\n* Patients must be at least 18 years old\n* Histologically confirmed prostate cancer\n* Clinical or pathologic stages T1c-T3b, Nx or N0-1, M0-1 (American Joint Committee on Cancer \\[AJCC\\] criteria 8th edition \\[Ed\\])\n* Planned definitive dose radiotherapy to the prostate or prostate bed\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 assessed within 90 days of enrollment\n* Patients must sign Institutional Review Board (IRB) approved study specific informed consent\n* Patients must complete all required pre-entry tests within the specified time frames\n* Patients must be able to start treatment (radiation) within 180 days of study registration\n* In case of confusion about the eligibility or ineligibility of an individual patient, the principal investigator (PI) can be used as the arbiter and a note to file will be added to the subject's regulatory binder to document outcome\n\nExclusion Criteria:\n\n* Previous pelvic radiation \\> 5 Gy\n* Planned delivery of radiotherapy to pelvic lymph nodes\n* Planned delivery of brachytherapy of the prostate\n* Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed)\n* Prior hip replacement or penile implant\n* Major medical, addictive, or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and\u002For interfere with follow-up. (consent by legal authorized representative is not permitted for this study)\n* Indwelling or intermittent urinary catheter use",{"count":308,"type":22},108,[129],"This phase III trial compares the effects of radiation therapy using RapidPlan, trademark, knowledge-based planning to human-driven planning in treating patients with prostate cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Successful delivery of radiation requires planning to develop a treatment plan for how and where the radiation is to be delivered. RapidPlan is a knowledge-based treatment planning tool that automatically creates an optimal treatment plan based on identified targets and organs at risk for radiation exposure. Human-driven treatment planning by a dosimetrist, the current standard of care, requires significant resources and time and may vary within and among radiation centers. Giving radiation therapy with RapidPlan knowledge-based planning may have similar or less side effects compared to human-driven planning in treating patients with prostate cancer.",[28],"2026-06-16",{"date":314,"type":34},"2026-06-18",{"date":316,"type":34},"2025-02-02",{"date":318,"type":22},"2033-05-28",{"name":188,"class":41},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":326,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":42},"100643062","targeted-early-detection-program-in-men-at-high-genetic-risk-for-prostate-cancer-100643062","NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer","Inclusion Criteria:\n\n* \\* Age 35-70 years\n\n  * Capable of providing informed consent\n  * Prognosis of \\> 5 years if affected by another cancer\n  * Patients need one to meet at least one of the following high genetic risk categories:\n\n    * Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53\n    * Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13\n    * Obligate carriers of the above mutations (e.g. their sisters\u002Fdaughters have known mutations)\n    * Men with any family history of above mutation\n    * Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50\n\nExclusion Criteria:\n\n* \\* Anuria\n\n  * Prior diagnosis or treatment for PCa\n  * Failure to provide informed consent\n  * Life expectancy \\\u003C 5 years","35 Years","70 Years",{"count":281,"type":22},"This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.",[28],"2026-06-08",{"date":333,"type":34},"2026-06-12",{"date":335,"type":34},"2017-01-01",{"date":337,"type":22},"2030-01",{"name":339,"class":41},"University of Michigan Rogel Cancer Center",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":49,"sex":17,"minAge":348,"maxAge":52,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":42},"100633427","urine-prostate-screening-integrated-with-mri-for-early-detection-of-prostate-cancer-uprise-trial-100633427","NCT07526545","Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial","UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)","UPRISE","Inclusion Criteria:\n\n* Males aged 50-75\n* PSA 3-20 ng\u002Fml within the previous 3 months\n* Fit to undergo all procedures listed in protocol per treating physician's discretion\n* No prostate biopsy in the past 4 years\n* No prostate MRI in the past 2 years\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Prior diagnosis of prostate cancer\n* Contraindication to MRI (e.g. claustrophobia, pacemaker)\n* Contraindication to prostate biopsy\n* Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work","50 Years",{"count":350,"type":22},800,[56],"This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.",[28],"NOT_YET_RECRUITING",{"date":356,"type":34},"2026-06-09",{"date":358,"type":22},"2026-09-01",{"date":360,"type":22},"2030-03-01",{"name":339,"class":41},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":49,"sex":50,"minAge":125,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":42},"100576714","breathing-practice-for-brain-and-mental-health-in-cancer-and-neurodegenerative-diseases-100576714","NCT06788886","Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases","Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study)","Inclusion Criteria:\n\n* STUDY 1: Participants must be physically fit enough to perform light exercise.\n* STUDY 1: Should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 1: Must have access to a smartphone or tablet.\n* STUDY 2: Participants must be physically fit enough to perform light exercise.\n* STUDY 2: Cancer patients may have prostate cancer, neuroendocrine tumor, or brain cancer in any stage.\n* STUDY 2: The main focus is on pairs of cancer patients and their respective caregivers, but individual cancer patients or individual caregivers are also acceptable.\n* STUDY 2: Participants should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 2: They also must have access to a smartphone or tablet.\n* STUDY 3: Participants must be physically fit enough to perform light exercise.\n* STUDY 3: The patient should have multiple sclerosis.\n* STUDY 3: Participants should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 3: They also must have access to a smartphone or tablet.\n\nExclusion Criteria:\n\n* STUDY 1: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants.\n* STUDY 1: Additionally, those with chronic medical conditions, including heart disease (coronary artery disease, congestive heart failure, hypertension, cardiac arrhythmia), chronic obstructive pulmonary disease (COPD), cystic fibrosis, cancer, diabetes, sleep apnea, aneurysms, and neurological conditions (epilepsy, Alzheimer's disease, Huntington' disease, essential tremor and Parkinson disease) are excluded.\n* STUDY 1: Participants with psychiatric conditions such as psychosis, suicidality, bipolar disorder, major depression, and substance use disorders are excluded.\n* STUDY 1: Participants serving as caregivers for any of the aforementioned conditions and for other illnesses such as cancer or neurological disorders, are also excluded.\n* STUDY 1: Further exclusions apply to those with severe vision, hearing impairments, have a body mass index (BMI) over 30, and those who are pregnant.\n* STUDY 1: Those planning to become pregnant during the study period will be excluded.\n* STUDY 2: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants are excluded, as are those with chronic lung disease (chronic obstructive pulmonary disease \\[COPD\\], cystic fibrosis), aneurysms, and those who are pregnant.\n* STUDY 2: Those planning to become pregnant during the study period will be excluded.\n* STUDY 3: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants are excluded, as are those with chronic lung disease (chronic obstructive pulmonary disease \\[COPD\\], cystic fibrosis), aneurysms, and those who are pregnant.\n* STUDY 3: Those planning to become pregnant during the study period will be excluded.","85 Years",{"count":371,"type":22},147,[56],"This clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with multiple sclerosis (MS) and cancer (along with their caregivers). The relationship between respiration, cardiovascular effects in the brain, mental health, and neurophysiological mechanisms are significant for patient populations facing complex health challenges, such as those with cancer and neurodegenerative disease, and their caregivers. By measuring oxygen delivery to brain tissues and cerebrospinal fluid flow, this trial may help researchers investigate the potential benefits of respiratory training for patients with MS and cancer and their caregivers.",[375,66,376,377,28],"Malignant Brain Neoplasm","Multiple Sclerosis","Neuroendocrine Tumor",{"date":379,"type":34},"2026-06-10",{"date":381,"type":34},"2025-02-05",{"date":383,"type":22},"2027-01-18",{"name":188,"class":41},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":146},"100517994","phase-3-multiparametric-ultrasound-for-the-diagnosis-of-clinically-significant-prostate-cancer-100517994","NCT06024772","Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer","Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)","Inclusion Criteria:\n\n* Subject must be scheduled for a prostate biopsy, based on an elevated PSA (\\> 3.0ng\u002Fml) per most recent National Comprehensive Cancer Network (NCCN) guidelines, elevated PSA velocity (\\> 0.75ng\u002Fml\u002Fyear), or abnormal digital rectal examination\n* Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate including the additional study biopsies\n* Subject must be a male at least 18 years of age when informed consent is obtained\n\nExclusion Criteria:\n\n* Participant in a clinical trial involving an investigational drug within the past 30 days\n* Patients with known or suspected hypersensitivity to perflutren, polyethylene glycol (PEG), or any other component of Definity\n* Previous treatment for prostate cancer, including hormone therapy\n* Clinically unstable, severely ill, or moribund as per treating physician",{"count":393,"type":22},300,[129],"This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.",[28],"2026-06-03",{"date":399,"type":34},"2026-06-05",{"date":401,"type":22},"2026-07",{"date":403,"type":22},"2027-02",{"name":405,"class":41},"Thomas Jefferson University",{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":42},"100598762","transperineal-micro-ultrasound-for-the-detection-of-prostate-cancer-during-biopsy-100598762","NCT07075705","Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy","Investigating the Feasibility of Using Transperineal Micro-Ultrasound to Detect Clinically Significant Prostate Cancer","Inclusion Criteria:\n\n* Men aged ≥ 18 years\n* Men scheduled for transrectal ultrasound guided prostate biopsy who have had a prebiopsy MRI. Therefore patients unable to have a prebiopsy MRI who have contraindications to MRI or unwilling to undergo MRI would be excluded\n* The participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board-approved written informed consent form before receiving any study-related procedure\n\nExclusion Criteria:\n\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate for study participation",{"count":414,"type":22},138,[56],"This clinical trial studies whether transperineal micro-ultrasound can be used to detect prostate cancer during biopsy. Transrectal ultrasound is often used during prostate biopsy. Transrectal ultrasound imaging is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Transrectal ultrasound is used to look for abnormalities in the rectum and nearby structures, including the prostate. The images are used to guide the prostate biopsy. Transperineal micro-ultrasound is completed by placing a probe over the skin between the scrotum and anus (perineum). It is a high-resolution ultrasound at 29 megahertz (MHz) (compared to traditional ultrasound at 6-9 MHz). This higher frequency allows for an improved spatial resolution. This improved spatial resolution is approximately the diameter of a prostatic duct, and therefore, may be able to visualize slight changes in the structure of prostatic ducts that are not possible with standard transrectal ultrasound. Transperineal micro-ultrasound may be more effective in detecting prostate cancer during biopsy.",[28],"2026-05-21",{"date":420,"type":34},"2026-05-22",{"date":422,"type":22},"2026-07-15",{"date":424,"type":22},"2027-01-15",{"name":426,"class":41},"Roswell Park Cancer Institute",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":49,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":447},"100398760","prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease-patrol-study-100398760","NCT04472338","Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study","PATROL: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease","Inclusion Criteria:\n\n* People with prostates ≥40 years of age\n* Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.\n\nExclusion Criteria:\n\n* Prior diagnosis of prostate cancer\n* Medical contraindication to any of the study procedures (e.g., prostate biopsy)\n* For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)\n* Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk\n* Unable to provide written informed consent\n* Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.",{"count":435,"type":22},450,"This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and\u002For tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.",[28],"2026-05-13",{"date":440,"type":34},"2026-05-15",{"date":442,"type":34},"2020-05-21",{"date":444,"type":22},"2030-08-31",{"name":446,"class":41},"University of Washington",8,{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":50,"minAge":125,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":42},"100516973","internet-based-lifestyle-intervention-to-eradicate-obese-frailty-in-prostate-cancer-survivors-ilive-100516973","NCT06011499","Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE","Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE)","iLIVE","Inclusion Criteria:\n\n* INTERVENTION PARTICIPANTS: Age 18 or older\n* INTERVENTION PARTICIPANTS: Diagnosed with histologically confirmed prostate cancer\n* INTERVENTION PARTICIPANTS: Received \\>= 6 months of ADT any time in the past 10 years\n* INTERVENTION PARTICIPANTS: Completed radiotherapy, chemotherapy and\u002For surgery \\> 6 weeks prior to\n* INTERVENTION PARTICIPANTS: No intent to start adjuvant chemotherapy or radiotherapy within 6 months of enrollment\n* INTERVENTION PARTICIPANTS: Overweight or obese (body mass index \\> 25 kg\u002Fm2 to BMI ≤ 50).\n* INTERVENTION PARTICIPANTS: Evidence of frailty by meeting three or more of the following frailty criteria: weakness, slowness, fatigue, inactivity, and\u002For illness\n* INTERVENTION PARTICIPANTS: Not currently engaging in structured diet or resistance strength training exercise program\n* INTERVENTION PARTICIPANTS: Willing to be randomized into either study arm and adhere to study protocol\n* INTERVENTION PARTICIPANTS: Home internet sufficient for videoconferencing\n* INTERVENTION PARTICIPANTS: Signed informed consent\n* IMPLEMENTATION PARTICIPANTS: Be a key stakeholder (i.e., healthcare provider or administrative, or intervention participant \\[completers, partial completers, or no participation\\])\n* IMPLEMENTATION PARTICIPANTS: Verbal informed consent following receipt of an information sheet\n\nExclusion Criteria:\n\n* INTERVENTION PARTICIPANTS: Unintentional weight loss \\> 5% within the last year\n* INTERVENTION PARTICIPANTS: Contraindication to moderate intensity exercise\n* INTERVENTION PARTICIPANTS: Health or medical condition that affects weight status\u002Fbody composition (e.g., Cushing's syndrome, uncontrolled hyper-\u002Fhypo- thyroidism)\n* INTERVENTION PARTICIPANTS: Active malignancy (other than non-melanoma skin cancer)\n* INTERVENTION PARTICIPANTS: Not fluent in English and therefore incapable of answer survey questions, following directions during exercise or performance testing, and providing informed consent in English\n* INTERVENTION PARTICIPANTS: Currently taking or have taken creatine supplement in the month preceding baseline creatine testing",{"count":457,"type":22},250,[56],"This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.",[28],"2026-05-06",{"date":463,"type":34},"2026-05-08",{"date":465,"type":34},"2024-03-12",{"date":467,"type":22},"2027-12-31",{"name":469,"class":41},"OHSU Knight Cancer Institute",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":476,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":487,"locationsCount":42},"100631757","get-fit-together-testing-a-socially-enhanced-exercise-program-in-older-men-with-prostate-cancer-100631757","NCT07504835","GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer","Inclusion Criteria:\n\n* Age 65 years of age or older.\n* Diagnosed with histologically confirmed prostate cancer.\n* Completed surgery, chemotherapy, radiation and\u002For systemic treatment (other than ADT) for cancer \\> 3 months ago.\n* Experiencing cancer loneliness.\n* Able to ambulate independently; reliance on assistive devices other than a wheelchair is allowed.\n* Willing to be randomized into any of the three study arms and attend 80% or more of planned exercise sessions.\n* Home internet sufficient for videoconferencing.\n\nExclusion Criteria:\n\n* Participating in regular group exercise and\u002For structured resistance training with other cancer survivors (\\> 1 exercise partner or groups of 3 or more).\n* Health or medical condition that affects movement or neurological disorder, or medication that contraindicates participation in live remote resistance exercise.\n* Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent.\n* Not fluent in English and therefore incapable of answer survey questions, following directions during exercise or performance testing, and providing informed consent in English.","65 Years",{"count":478,"type":22},150,[56],"This clinical trial tests the impact of different levels of social support on the benefits of exercise in older men with prostate cancer. This trial compares a socially-enhanced supervised group exercise program to a supervised group exercise program with no social enhancement, and an unsupervised home-based program on cancer loneliness, social isolation, mental and physical health in older prostate cancer survivors. All study arms exercise for 6 months and outcomes are measured at baseline, 3 and 6 months. The primary outcome is cancer loneliness with secondary outcomes of mental and physical health.",[28],"2026-04-30",{"date":461,"type":34},{"date":485,"type":34},"2026-04-15",{"date":74,"type":22},{"name":469,"class":41},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":42},"100602671","a-point-of-prostate-cancer-diagnosis-virtual-reality-assistant-intervention-in-supporting-newly-diagnosed-black-men-100602671","NCT07126548","A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men","A Pragmatic Clinical Trial to Evaluate the Effect of a Point of Prostate Cancer Diagnosis (PPCD) Virtual Reality Assistant (ViRA) in Supporting Newly Diagnosed Black Men","Inclusion Criteria:\n\n* African American\u002FBlack male\n* Diagnosed with CaP within two months\n* Be a patient at a participating clinic or affiliates with one of our community sites\n* Consent to participating in the study\n\nExclusion Criteria:\n\n* Do not speak or understand English\n* Unable to read or write",{"count":281,"type":22},[56],"This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American\u002FBlack men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American\u002FBlack men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American\u002FBlack men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American\u002FBlack men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.",[28],{"date":500,"type":34},"2026-04-20",{"date":502,"type":22},"2027-06-01",{"date":504,"type":22},"2029-09-02",{"name":188,"class":41},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":42},"100498139","phase-2-pembrolizumab-plus-177lu-psma-617-in-patients-with-castration-resistant-prostate-cancer-100498139","NCT05766371","Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer","A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer","Inclusion Criteria:\n\n1. Histologically confirmed prostate adenocarcinoma that is progressive metastatic castration-resistant prostate cancer by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria at the time of study entry.\n2. Male participants who are at least 18 years of age on the day of signing informed consent.\n3. Castrate level of serum testosterone at study entry (\\\u003C 50 ng\u002FdL). Note: Participants without prior bilateral orchiectomy are required to remain on Luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study.\n4. Prior progression on at least one second generation androgen signaling inhibitor including abiraterone, apalutamide, darolutamide, and\u002For enzalutamide.\n5. Adverse events related to prior anti-cancer treatment (excluding LHRH analogs) must have recovered to Grade \\\u003C= 1 (except for any grade alopecia and grade \\\u003C= 2 neuropathy).\n6. Prior radiotherapy is allowed if the last radiotherapy treatment was greater than 2 weeks from start of study treatment on cycle 1, day 1 (C1D1). Note- Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\\\u003C=2 weeks of radiotherapy) to non-central nervous system (CNS) disease.\n7. At least one Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) (PSMA PET) avid lesion on screening PSMA PET. A positive lesion is defined as uptake above background liver.\n8. Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C= 1 (Karnofsky \\>= 70%).\n9. Demonstrates adequate organ function as defined below:\n\n   1. Adequate bone marrow function:\n\n      * absolute neutrophil count \\>=1,500\u002Fmicroliter (mcL)\n      * platelets \\>=100,000\u002FmcL\n      * hemoglobin \\> 9.0 g\u002FdL\n   2. Adequate hepatic function:\n\n      * total bilirubin \\\u003C= 1.5 x upper limit of normal (ULN). In patients with known or suspected Gilbert's disease, direct bilirubin \\\u003C= ULN\n      * aspartate aminotransferase (AST)\u002Fserum glutamic-oxaloacetic transaminase (SGOT) \\\u003C= 2.5 x institutional ULN (\\\u003C= 5 x ULN in patients with liver metastases)\n      * alanine aminotransferase (ALT)\u002Fserum glutamic-pyruvic transaminase (SGPT) \\\u003C= 2.5 x institutional upper limit of normal (\\\u003C= 5 x ULN in patients with liver metastases)\n   3. Adequate renal function:\n\n      * creatinine \\\u003C= 1.5 x within institutional upper limit of normal OR\n      * creatinine clearance Glomerular filtration rate (GFR) \\>= 50 mL\u002Fmin\u002F1.73 m\\^2, calculated using the Cockcroft-Gault equation or 24 hour urine collection.\n10. Participants must use appropriate methods of contraception during study treatment and for at least 6 months after last study treatment. Patients who are sexually active should consider their female partner to be of childbearing potential if she has experienced menarche and is not postmenopausal (defined as amenorrhea \\> 24 consecutive months) or has not undergone successful surgical sterilization. Even women who use contraceptive hormones (oral, implanted, or injected), an intrauterine device, or barrier methods (diaphragms, condoms, spermicide) should be considered to be of childbearing potential. Patients who have undergone vasectomy themselves should also be considered to be of childbearing potential. Acceptable methods of contraception include continuous total abstinence, or double-barrier method of birth control (e.g., condoms used with spermicide, or condoms used with oral contraceptives). Periodic abstinence and withdrawal are not acceptable methods of contraception.\n11. Participants must provide consent to comply to recommended radioprotection precautions during study.\n12. Participants willing to undergo a tumor biopsy. Bone or soft tissue lesion is allowed. Note: The biopsy can be waived if there is no safely accessible lesion in the judgement of the treating investigator.\n13. Participants with previously treated brain metastases are eligible provided the following criteria are all met:\n\n    1. Last treatment was \\> 28 days prior to C1D1.\n    2. No evidence of new\u002Fprogressive brain metastases is observed on magnetic resonance imaging (MRI) obtained during screening window\n    3. Patient is clinically stable without requirement of steroid treatment for at least 14 days prior to first dose of study treatment on C1D1.\n14. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n15. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. De novo small cell neuroendocrine prostate cancer will not be allowed due to putative lower PSMA expression in this tumor subtype. Note-Treatment-emergent small cell neuroendocrine prostate cancer detected in metastatic tumor biopsy is not excluded.\n2. Soft tissue lesions (lymph nodes \\> 1.5 centimeter (cm) in short axis, visceral\u002Fsoft tissue lesions \\> 1 cm) on screening Computerized tomography (CT) that are negative on PSMA PET. Note: Negative lesions on PSMA PET are defined as those with uptake below the background liver.\n3. Has received other systemic anti-cancer therapies administered within 14 days, or 5 half-lives, whichever is shorter, prior to initiation of study treatment. Note: LHRH analogues are the exception.\n4. Untreated brain metastases at study entry.\n5. Receipt of prior PSMA-directed treatment (e.g., radiotherapy, immunotherapy, or antibody-drug conjugate).\n6. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-Programmed cell death-ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX 40, CD137).\n7. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment on C1D1. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n8. Receipt of \\> 2 lines of prior taxane-based chemotherapy.\n9. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n10. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazole, carbimazole, etc.) that function to decrease the generation of thyroid hormone by a hyper-functioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.\n11. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of \\> 10 mg daily or other form of immunosuppressive therapy within 7 days prior to first dose of study drug.\n12. Has a history of (non-infectious) ≥ grade 2 pneumonitis\u002Finterstitial lung disease that required steroids within past 2 years or has current ≥ grade 1 pneumonitis\u002F interstitial lung disease at the time of study enrollment.\n13. Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug on C1D1. Note-Administration of a killed vaccine is allowed.\n14. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.\n15. Has clinically significant cardiovascular disease including, but not limited to:\n\n    1. Uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure.\n    2. Uncontrolled angina, history of myocardial infarction, unstable angina, or stroke within 6 months before study entry.\n    3. Clinically significant arrhythmias not controlled by medication. Note: Chronic rate controlled, or paroxysmal atrial fibrillation\u002Fflutter is not an exclusion to study participation.\n16. Prior external beam radiation involving \\> 25 percent (%) of bone marrow or within 14 days of start of protocol therapy on C1D1.\n17. Major surgery within 28 days of study treatment. Note: If participant received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment on C1D1. Minor procedures (e.g., biopsy, cataract surgery, stent placement, endoscopy) are not considered major surgery.\n18. Has an active infection requiring intravenous antibiotics within 7 days prior to C1D1.\n19. Has a known history of Hepatitis B infection (defined as Hepatitis B surface antigen (HBsAg) reactive) or known active Hepatitis C virus infection (defined as (HCV RNA) \\[qualitative\\] detected, with the following exceptions:\n\n    1. Participants who are HbsAg positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to study entry\n    2. Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. Participants must have completed curative anti-viral therapy at least 4 weeks prior to study entry.\n20. Has a known history of active Bacillus Tuberculosis (TB).\n21. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n22. History of bleeding diathesis and currently on anti-coagulation therapy that cannot be safely discontinued for the tumor biopsy procedure.\n23. Any condition that, in the opinion of the Principal Investigator, would impair the participant's ability to comply with study procedures.",{"count":514,"type":22},48,[25],"This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant prostate cancer (mCRPC) who have previously progressed on at least one prior androgen pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide).",[518,519,92,28],"Castrate Resistant Prostate Cancer","Metastatic Castration-resistant Prostate Cancer",{"date":521,"type":34},"2026-04-17",{"date":523,"type":34},"2023-12-15",{"date":525,"type":22},"2031-05-31",{"name":527,"class":41},"University of California, San Francisco",{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":42},"100605554","early-phase-1-comparing-a-new-psma-imaging-agent-to-mri-for-detecting-prostate-cancer-beacon-trial-100605554","NCT07164027","Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","Beacon: Prospective Assessment of Flotufolastat F 18 PSMA and MRI in the Diagnosis of Clinically Significant Prostate Cancer","Inclusion Criteria:\n\n* Men aged 18-90 at study enrollment\n* Have at least one PI-RADS 3-5 lesion on MRI within the 12 months prior to enrollment\n\nExclusion Criteria:\n\n* Contraindication to flotufolastat F 18 PET CT\n* Contraindication to ultrasound-guided prostate biopsy\n* Previous treatment of prostate cancer\n* Unable to discontinue blood thinners for 7 days prior to biopsy\n* Any investigational agents within 42 days prior to the day of the first dose\n* Not able to understand and to follow study instructions and requirements. This also includes the inability to complete the study imaging and or biopsy procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)","90 Years",{"count":220,"type":22},[222],"This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \\[PSMA\\] imaging agent) with positron emission tomography (PET)\u002Fcomputed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET\u002FCT. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes X-rays that track the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. The PET\u002FCT scanner combines the PET and the CT scanners into a single device. A targeted prostate biopsy refers to using advanced imaging for guidance when taking samples (biopsies) of the prostate. This method can fuse (combine) PET\u002FCT images with real-time ultrasound during a prostate biopsy. PSMA PET\u002FCT scans have the potential for guiding prostate biopsies. Using image fusion technology, they can increase detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy. Improved detection of prostate cancer using PSMA PET\u002FCT guidance may better inform men and their clinicians about prostate cancer risk and management. This study attempts to determine how often prostate cancer is found when using PSMA PET\u002FCT scan images during a biopsy versus the conventional magnetic resonance imaging-guidance.",[28],"2026-03-06",{"date":542,"type":34},"2026-03-10",{"date":544,"type":34},"2025-11-14",{"date":546,"type":22},"2037-01-28",{"name":233,"class":41},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":564,"locationsCount":42},"100532703","phase-2-phase-2-randomized-trial-of-flexible-dosing-schedule-of-177lu-psma-617-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer-flex-mrt-100532703","NCT06216249","Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT)","Inclusion Criteria:\n\n* Patients must have prostate cancer proven by histopathology\n* Patients must have ≥ 1 metastatic lesion by any imaging (CT, magnetic resonance imaging \\[MRI\\], bone scan, PET)\n* Patients must have received at least one regimen of chemotherapy for mCRPC\n* Patients must have received at least one androgen-receptor signaling inhibitors (ARSI)\n* Patients must be eligible by PSMA PET VISION criteria. PSMA PET\u002FCT must be performed within 8 weeks of planned first cycle of 177Lu-PSMA-617\n* White blood cell (WBC) ≥ 2,500\u002Ful\n* Platelets (PLT) ≥ 100,000\u002Ful\n* Hemoglobin (Hb) ≥ 9.0 g\u002Fdl\n* Absolute neutrophil count (ANC) ≥ 1,500 ul\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Patients must be adults ≥ 18 years of age\n* Patients must have the ability to understand and sign an approved informed consent form (ICF)\n* Patients must have the ability to understand and comply with all protocol requirements\n\nExclusion Criteria:\n\n* Prior cycle of 177Lu-PSMA-617 therapy\n* Less than 6 weeks between last myelosuppressive therapy (including docetaxel, cabazitaxel, strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, hemi-body irradiation) and first cycle of 177Lu-PSMA-617 therapy\n* Glomerular filtration rate (GFR) \\\u003C 50 ml\u002Fmin\n* Urinary tract obstruction or marked hydronephrosis",{"count":242,"type":22},[25],"In advanced metastatic castration resistant prostate cancer (mCRPC) progressing after chemotherapy and androgen receptor (AR)-targeted therapy 177Lu-PSMA-617 is an effective treatment. 177Lu-PSMA-617 RLT is administered with a fixed schedule: 6 treatment cycles, administered every 6 weeks. However, the optimum number of cycles of 177Lu-PSMA in patients who show good response remains unknown. Some patients may benefit from more than 6 cycles of therapy. Additionally, some patients experience a complete or almost complete response before the last cycle. It is unclear whether these patients benefit from the subsequent remaining treatment cycle(s). A treatment holiday period would spare these patients some exposure to the therapy agent and avoid potentially unnecessary toxicity when treatment efficacy is already maximal and additional treatment effect cannot be expected. This randomized phase 2 study compares a group of patients treated with LuPSMA on a flexible and extended dosing schedule including \"treatment holiday\" periods (investigational arm, up to 12 cycles, as described below) to a control group treated with a fixed dosing schedule of 6 treatments cycles maximum administered every 6 weeks. The flexible dosing schedule in the investigational arm will be based on single photon emission computed tomography (SPECT)\u002Fcomputed tomography (CT) response assessments obtained 24h after injection of LuPSMA therapy cycle. The response assessment during treatment holiday period will be based on positron emission tomography\u002Fcomputed tomography (PET\u002FCT) every 12 weeks. Single-time point SPECT\u002FCT dosimetry protocol at every cycle will be performed and will allow to determine the number of cycles that subjects may receive under the study without exceeding the kidney dose threshold.",[28,559],"Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8",{"date":542,"type":34},{"date":562,"type":34},"2024-08-01",{"date":115,"type":22},{"name":233,"class":41},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":263,"phases":4,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":146},"100521261","longitudinal-advanced-prostate-cancer-cohort-lapcc-100521261","NCT06067295","Longitudinal Advanced Prostate Cancer Cohort (LAPCC)","Inclusion Criteria:\n\n* Men of all racial and ethnic groups 18 years of age or older\n* Men with a diagnosis of advanced (metastatic) prostate cancer who are scheduled to begin a new systemic treatment (including first or subsequent lines of therapy)\n* Prior participation on clinical trials is allowed\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Any other malignancy, unless previously treated with curative intent and the subject has been disease free for 3 years or longer",{"count":393,"type":22},"This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). By collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, diet, and quality of life) researchers hope to learn more about prostate cancer and ways to improve outcomes in the future.",[28],{"date":542,"type":34},{"date":576,"type":34},"2023-02-21",{"date":467,"type":22},{"name":579,"class":41},"University of Southern California",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":588,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":42},"100621929","decision-support-tool-to-enhance-germline-genetic-testing-for-patients-with-prostate-cancer-100621929","NCT07377006","Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer","Efforts to Enhance Germline Genetic Testing at Lyndon B. Johnson Hospital","Inclusion Criteria:\n\n* Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital\n* Were recommended for germline genetic testing by their oncology provider\n* Can provide informed consent\n* Can communicate in English or Spanish\n\nExclusion Criteria:\n\n* Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition",{"count":308,"type":22},[56],"This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.",[28],"2026-02-17",{"date":593,"type":34},"2026-02-18",{"date":595,"type":22},"2026-10-01",{"date":597,"type":22},"2030-12-31",{"name":299,"class":41}]